The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
Open accessAbstract
BACKGROUND.: Radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ) is now the standard of care for patients with newly diagnosed glioblastoma. The occurrence of pseudo‐progression directly after RT is a recognized phenomenon, but to the authors' knowledge its incidence after combined RT/TMZ is unknown. The occurrence of early pseudo‐progression was retrospectively assessed in a cohort of malignant glioma patients treated with RT/TMZ. METHODS.: The pre‐RT and post‐RT brain scans from patients treated with RT/TMZ for a malignant glioma were reviewed. Scans were made before the start of RT, 4 weeks after the end of RT, and every 3 months thereafter. In addition, information was collected regarding clinical signs and symptoms, dexamethasone dose, histology, and survival. RESULTS.: Eighty‐five patients were identified. In 36 patients (42%) the first follow‐up scan 4 weeks after the end of RT indicated disease progression. Of these 36 patients, 18 (50%) were diagnosed with pseudo‐progression. None of the patients received additional treatment other than TMZ. Six of 18 patients with pseudo‐progression and 12 of the 18 patients with real tumor progression developed new clinical signs and symptoms during RT or in the first 4 weeks thereafter. CONCLUSIONS.: Up to 50% of malignant glioma patients treated with RT/TMZ and progression immediately after RT develop pseudo‐progression. The current study data support the idea to continue TMZ in the case of progressive lesions immediately after RT/TMZ. Surgery should be considered in symptomatic cases. The inclusion of patients with progressive lesions developing directly after chemoradiation in studies regarding recurrent gliomas will lead to an overestimation of the results. Cancer 2008. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 840
Ruben, J. D., Dally, M., Bailey, M., Smith, R., McLean, C. A., & Fedele, P. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.12.002 · Cited by 492
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. C. Y., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. E., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 357
Self-citationEarly necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
Chamberlain, M. C., Glantz, M. J., Chalmers, L., Van Horn, A., & Sloan, A. E. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9241-y · Cited by 343
Ballman, K. V., Buckner, J. C., Brown, P. D., Giannini, C., Flynn, P. J., LaPlant, B. R., & Jaeckle, K. A. (2007) · Neuro-Oncology · doi:10.1215/15228517-2006-025 · Cited by 314
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Box, P. (2005) · Dkgest of the World Latest Medical Information · Cited by 299
Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms
Chakravarti, A., Erkkinen, M. G., Nestler, U., Stupp, R., Mehta, M., Aldape, K., Gilbert, M. R., Black, P. M., & Loeffler, J. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0596 · Cited by 223
Cited by
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationStandards of care for treatment of recurrent glioblastoma—are we there yet?
Weller, M., Cloughesy, T., Perry, J. R., & Wick, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos273 · Cited by 771
Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
Hygino da Cruz, L. C., Rodriguez, I., Domingues, R. C., Gasparetto, E. L., & Sorensen, A. G. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2397 · Cited by 545
Wen, P. Y., van den Bent, M., Youssef, G., Cloughesy, T. F., Ellingson, B. M., Weller, M., Galanis, E., Barboriak, D. P., de Groot, J., Gilbert, M. R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01059 · Cited by 519
Self-citationCurrent Clinical Brain Tumor Imaging
Villanueva-Meyer, J. E., Mabray, M. C., & Cha, S. (2017) · Neurosurgery · doi:10.1093/neuros/nyx103 · Cited by 453
Metadata
- Authors
- Taal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E., Swaak‐Kragten, A. T., Sillevis Smitt, P. A. E., van Es, C. A., & van den Bent, M. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-07-08
- Volume
- 113
- Issue
- 2
- Pages
- 405-410
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2092736872
- Cited by
- 465
- References
- 9
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.